Abhishek, Swetabh and Richard transform drug discovery using machine learning!
The exponential growth of biomedical molecular data has reduced its usability, eventually slowing down the drug discovery process, making it more expensive. Elucidata’s proprietary SaaS platform - Polly, uses machine learning (ML) to accelerate the drug discovery process. The platform hosts a rich archive of over 230,000 multi-omic datasets, curated semi-automatically, with over 50,000 new datasets added each month.
Today, Elucidata has 35+ research partners from premier biopharma companies and research labs across the globe using Polly and supports the discovery programs at Pfizer, Agios Pharmaceuticals, Genentech and Yale.
- DR ABHISHEK JHA,
CO-FOUNDER & CEO
- SWETABH PATHAK,
CO-FOUNDER & CTO
Dr Abhishek Jha
Co-Founder & CEO
Co-Founder & CTO
Data & Technology
IvyCap leads pre-Series A funding in health-tech firm Elucidata
Elucidata, a biomedical molecular data company, on Thursday said it has raised $5 million (Rs 36.4 crore) in its pre-Series A funding round led by IvyCap Ventures.Know more
Elucidata Announces A $5 Million Pre-Series A Funding Round Led By IvyCap Ventures
The financing round also saw participation from Hyperplane Venture Capital and several angel investors. Elucidata will invest in go-to-market initiatives and in their data platform.Know more
Biomedical Data Startup Elucidata Bags $16 Mn To Scale SaaS Platform Polly
The startup will use the funding to deepen product capabilities in translational drug research and allied marketsKnow more